Arto A Palmu

Summary

Publications

  1. doi request reprint Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial
    Arto A Palmu
    Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Tampere, Finland Electronic address
    Lancet Infect Dis 14:205-12. 2014
  2. doi request reprint Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial
    Arto A Palmu
    Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Tampere, Finland
    Lancet 381:214-22. 2013
  3. doi request reprint Nasopharyngeal carriage of Streptococcus pneumoniae and pneumococcal urine antigen test in healthy elderly subjects
    Arto A Palmu
    National Institute for Health and Welfare, Helsinki, Finland
    Scand J Infect Dis 44:433-8. 2012
  4. doi request reprint Efficacy of pneumococcal conjugate vaccine against PCR-positive acute otitis media
    Arto A Palmu
    National Institute for Health and Welfare, Helsinki, Finland Tampere School of Public Health, Tampere, Finland
    Vaccine 27:1490-1. 2009
  5. doi request reprint Presence of capsular locus genes in immunochemically identified encapsulated and unencapsulated Streptococcus pneumoniae sputum isolates obtained from elderly patients with acute lower respiratory tract infection
    Paula Kurola
    National Institute for Health and Welfare, Oulu, Finland
    J Med Microbiol 59:1140-5. 2010
  6. doi request reprint Incidence and etiology of community-acquired pneumonia in the elderly in a prospective population-based study
    Arto A Palmu
    From the National Institute for Health and Welfare, Helsinki, Finland
    Scand J Infect Dis 46:250-9. 2014
  7. doi request reprint Acute otitis media replacement and recurrence in the Finnish otitis media vaccine trial
    Jukka Jokinen
    Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland
    Clin Infect Dis 55:1673-6. 2012
  8. doi request reprint Long-term effect of pneumococcal conjugate vaccines on tympanostomy tube placements
    Ilona Sarasoja
    Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Tampere, Finland
    Pediatr Infect Dis J 32:517-20. 2013

Detail Information

Publications8

  1. doi request reprint Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial
    Arto A Palmu
    Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Tampere, Finland Electronic address
    Lancet Infect Dis 14:205-12. 2014
    ..We assessed the effect of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10; GlaxoSmithKline) on antimicrobial purchases...
  2. doi request reprint Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial
    Arto A Palmu
    Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Tampere, Finland
    Lancet 381:214-22. 2013
    ....
  3. doi request reprint Nasopharyngeal carriage of Streptococcus pneumoniae and pneumococcal urine antigen test in healthy elderly subjects
    Arto A Palmu
    National Institute for Health and Welfare, Helsinki, Finland
    Scand J Infect Dis 44:433-8. 2012
    ..Lower carriage rates have been reported in adults and only sparse data are available for the elderly. We sampled healthy elderly subjects for nasopharyngeal carriage to assess the prevalence of pneumococcal carriage using various assays...
  4. doi request reprint Efficacy of pneumococcal conjugate vaccine against PCR-positive acute otitis media
    Arto A Palmu
    National Institute for Health and Welfare, Helsinki, Finland Tampere School of Public Health, Tampere, Finland
    Vaccine 27:1490-1. 2009
    ..The data do not support effect of PncCRM on AOM in which only Ply-PCR suggests pneumococcal etiology...
  5. doi request reprint Presence of capsular locus genes in immunochemically identified encapsulated and unencapsulated Streptococcus pneumoniae sputum isolates obtained from elderly patients with acute lower respiratory tract infection
    Paula Kurola
    National Institute for Health and Welfare, Oulu, Finland
    J Med Microbiol 59:1140-5. 2010
    ..002). The cpsB PCR developed here was found to be a rapid and reliable method to detect the pneumococcal capsule locus and may have potential in sputum diagnostics when investigating the pneumococcal aetiology of CAP...
  6. doi request reprint Incidence and etiology of community-acquired pneumonia in the elderly in a prospective population-based study
    Arto A Palmu
    From the National Institute for Health and Welfare, Helsinki, Finland
    Scand J Infect Dis 46:250-9. 2014
    ..Specific objectives were to demonstrate setting feasibility, to construct a case definition for Pnc CAP, and to estimate its incidence...
  7. doi request reprint Acute otitis media replacement and recurrence in the Finnish otitis media vaccine trial
    Jukka Jokinen
    Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland
    Clin Infect Dis 55:1673-6. 2012
    ..We found evidence of replacement disease occurring early during the trial follow-up and little vaccine impact on recurrent overall AOM episodes...
  8. doi request reprint Long-term effect of pneumococcal conjugate vaccines on tympanostomy tube placements
    Ilona Sarasoja
    Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Tampere, Finland
    Pediatr Infect Dis J 32:517-20. 2013
    ..This study aimed to assess the effectiveness of pneumococcal conjugate vaccines PncCRM and PncOMPC from 2 up to 13 years of age...